The company is offering a fresh issue of 1.33 crore equity shares at a price band of ₹86-91 per share.
The grey market premium (GMP) for Anlon Healthcare is quoting at about 6% over the upper end of the price band.However, it is important to note that grey market premiums are just an indicator of how the company’s shares are stacked up in the unlisted market and are subject to change rapidly.
Brokerage house Anand Rathi has given a ‘Subscribe – Long Term’ rating to the issue, highlighting Anlon’s strong and diversified product portfolio, scalable business model, and regulatory approvals across multiple jurisdictions.The note, however, cautions that the IPO is “fully priced” at a P/E of 19x FY25 earnings and an EV/EBITDA of 16.7x. It recommends the issue primarily for investors with a long-term horizon.
The IPO proceeds will be deployed for expansion of manufacturing facilities, repayment of certain borrowings, and general corporate purposes.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates (Pharma Intermediate) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (APIs) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (“FDF”) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products.
The issue is managed by Interactive Financial Services with KFin Technologies as the registrar.
The allotment for the Anlon Healthcare IPO is expected to be finalised on September 1. Shares are scheduled to list on NSE SME on September 3.
First Published: Aug 26, 2025 12:56 PM IS
